Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Researchers conducted a systematic review to assess the effect of certain cancer treatments on pregnancy and neonatal outcomes.

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Researchers sought to determine whether primary anti-infectious prophylaxis would reduce the incidence of febrile neutropenia and treatment interruptions in older patients with iBC-NHLs.

Survival rates also are lower for Black versus White people across various cancer types and categories of urbanicity.

The effectiveness of the Interaktor app was evaluated in a randomized trial of patients undergoing radiotherapy for prostate cancer monitor and manage their symptoms.

Researchers sought to determine whether elranatamab would lead to durable responses in patients with relapsed or refractory multiple myeloma.

Lower mortality risk seen for those who improved guideline concordance after diagnosis or maintained high concordance.